The activation of T cells plays a central role in antitumor immunity. In order to activate naïve T cells, two key signals are required. Signal one is provided through the T-cell receptor (TCR) while signal two is that of costimulation. The CD28:B7 molecules are one of the best-studied costimulatory pathways, thought to be the main mechanism through which primary T-cell stimulation occurs. However, a number of molecules have been identified which serve to amplify and diversify the T-cell response, following initial Tcell activation. These include the more recently described 4-1BB:4-1BB ligand (4-1BBL) molecules. 4-1BB:4-1BBL are a member of the TNFR:TNF ligand family, which are expressed on T cells and antigen-presenting cells (APCs), respectively. Therapies utilizing the 4-1BB:4-1BBL signaling pathway have been shown to have antitumor effects in a number of model systems. In this paper, we focus on the 4-1BB:4-1BBL costimulatory molecules. In particular, we will describe the structure and function of the 4-1BB molecule, its receptor and how 4-1BB:4-1BBL costimulation has and may be used for the immunotherapy of cancer.
I
n antitumor immunity, cell-mediated responses play a central role. In order to activate a naı¨ve T cell, two signals are thought to be requisite. The primary signal or signal one occurs through the TCR:MHC:Ag (antigen) complex while the second signal or signal two is provided through costimulation. 1 The CD28:B7 pathway (reviewed elsewhere 2, 3 ) in conjunction with the TCR:MHC:Ag stimulus induces high levels of IL-2 production from T cells. This signaling can provide the essential survival signals, [4] [5] [6] preventing the induction of apoptosis through activation induced cell death (AICD) and the induction of T cell anergy which occurs in response to signal one alone. 7, 8 A number of molecules have been identified which function to further enhance and extend the activation of T cells. Costimulatory molecules including 4-1BBL, CD40, OX40L and CD70 have been reviewed previously. 9 In this report, we focus solely on the role of 4-1BB and its receptor 4-1BBL in costimulation and discuss its potential as a target for the immunotherapy of cancer.
Characterization of 4-1BB gene and protein 4-1BB was first identified in mice by a modified differential screening procedure.
10,11 4-1BB was found to map to murine chromosome 4 at the 75.5 cM position (Fig 1ai) . In mice, the 4-1BB gene spans approximately 13 kb consisting of 10 exons, two of them in the 5 0 untranslated regions and eight in the coding region.
11
Analysis of the nucleotide sequence of 4-1BB revealed a single open reading frame, which codes for a polypeptide 256 amino acids (a.a.) in length with a calculated molecular mass of 27.5 kDa. The first 23 a.a. was shown to be a signal peptide, followed by a cysteine-rich region, which comprised of four potential TNFR motifs, of which the first was partial and the third distinct from those of the TNFR. 11 Almost 30% of the a.a. between residues 140-185, which follows the ligandbinding domain, were serine or threonines, providing a potential site for O-linked glycosylation while a.a. 186-211 constitute the hydrophobic transmembrane domain which is followed by the stop-transfer sequence containing several basic residues. 11 The carboxyl terminal part of the cytoplasmic domain contains two short runs of three and four acidic residues, respectively, and a sequence of five glycines followed by a tyrosine (Fig  1bi) .
brane region of 27 a.a. between positions 187-213, and finally a short intracellular domain of 42 a.a (Fig 1bii) . 13 The molecular weight of the protein was calculated to be 27 kDa 15 and was shown to be 60% identical to murine 4-1BB (Fig 1c) . 13 In the cytoplasmic domain, five regions of a.a. sequences were conserved between mice and human, indicating that these residues might be important for 4-1BB function. 13 
Characterization of 4-1BBL gene and its protein
The presence of a ligand for 4-1BB was first confirmed in the EL4 cell line through its binding with a fusion 4-1BB/ Fc protein, the 4-1BBL gene was then cloned through the screening of an EC1 cDNA expression library. 16 Murine 4-1BBL consists of 309 a.a. polypeptide. Hydrophobicity analysis predicted that a.a. 83-103 were a signal hydrophobic domain, while the absence of a signal sequence suggested that 4-1BBL was a type II membrane glycoprotein with an extracellular carboxyterminal domain. 16 The 4-1BBL gene maps to murine chromosome 17.
16
Human 4-1BBL was first isolated in 1994 by Alderson et al. 13 They used a fusion protein consisting of the extracellular portion of human 4-1BB coupled to the Fc region of human immunoglobulin (Ig) G 1 to identify and clone the gene for human 4-1BBL from an activated CD4 þ T-cell clone using a direct expression cloning strategy. Sequence analysis revealed that human 4-1BBL consisted of 254 a.a. and shared a 36% identity with murine 4-1BBL. 13 The cysteine residues were not conserved between mice and humans, which raised the possibility that these two genes may in fact represent two distinct ligands for 4-1BB. 13 Fluorescence in situ hybridization analyses or FISH analysis showed that the human 4-1BBL gene mapped to chromosome 19 in the region 19p13.3. 13 Like murine 4-1BBL was demonstrated to be a type II glycoprotein with a single predicted transmembrane segment. 13 Figure 1 Diagrammatic representation of mouza and human 4-1BB chromosomal localizations, structure of their respective proteins and amino-acid sequence homology. (a) The chromosomal location of the 4-1BB gene on (i) chromosome 4 on 4E2 on mice and on chromosome 1p36.2 in humans. In humans and mice the chromosomal location of 4-1BB is close to other members of the TNFR family including TNFR2, CD30, OX40, and APO3. In humans, the 1p36 region is associated with deletions and rearrangements in several malignancies. (b) Diagrammatic representation of the structure of the 4-1BB protein shown in (i) mice and (ii) humans. Some of the important functional domains of these proteins are illustrated, such as the signal peptide, ligand binding, transmembrane and intracellular domains as described in references 11 and 13. (c) The a.a. sequence homology between the murine and human 4-1BB molecules is shown in (i) with M4-1BB and H4-1BB representing murine and human 4-1BB, respectively. Differences in the amino-acid sequences between murine and human are indicated in black block and approximately 60% sequence similarity exists between these two species. In (ii) the cytoplasmic tail of murine and human 4-1BB a.a. sequence are shown and conserved regions are indicated; it has been suggested that the cytoplasmic region mediates signal transduction.
Expression of 4-1BB and 4-1BBL in vivo
4-1BB was found to be induced on CD4 þ and CD8 þ T cells in mice and humans. [17] [18] [19] [20] The expression in mice takes several hours following stimulation, slowly increasing and peaking at 60 hours and declining again by 110 hours. 16, 19, 21 In human, 4-1BB mRNA was detected 1.5 hours after stimulation on T lymphocytes, reaching maximal levels at 8 hours, and declining to background levels by 48 hours. 18 In addition to CD4 þ and CD8 þ T cells, 4-1BB was also expressed on activated natural killer (NK), 22 dendritic cells (DC) 23 as well as neutrophils 24 in mice. In humans, the expression of 4-1BB was been reported in follicular DCs, 25 monocytes, 26 hepatoma cells 18 and blood vessels from individuals with malignant tumors. 27 The soluble form of 4-1BB was also reported in the serum of patients with rheumatoid arthritis. 28 The expression of 4-1BB increases in human peripheral blood mononuclear cells after exposure to mitomycin and other DNAdamaging agents, such as doxorubicin, bleomycin and girradiation. 29 Through the use of 5 0 deletion constructs of the human 4-1BB promoter in luciferase reporter assays, it was found that the transcriptional elements mediating 4-1BB upregulation were located in the region between 0.9 and 1.1 kb from the translational start site. 30 Characterization of these sites by electrophoretic mobility shift assay and sitedirected mutagenesis revealed that nuclear factor-kappa B (NF-kB) and activating protein-1 (AP-1) were involved, and MEK and c-Jun N-terminal kinase-1 (JNK-1) activity were required for activation-dependent 4-1BB upregulation. Thus, NF-kB and AP-1 were involved in the TCR stimulation-dependent transcriptional regulation of the 4-1BB promoter. 30 When comparing 4-1BB with CD28, it becomes apparent that the expression patterns of these two costimulatory molecule receptors were very different in T cells. CD28 was expressed on all murine T cells and on the majority human T cells. 7, 8 However, upon activation of T cells, a dramatic increase in CD28 expression was reported in terms of both the mRNA and protein levels. 31 
CD4
þ CD25 þ regulatory T cells express 4-1BB constitutively, 32 ,33 while 4-1BB expression was induced from undetectable levels on naı¨ve cells, adding credence to the suggestion that 4-1BB expression was a result of the upregulation of the B7 costimulatory molecules through CD28 signaling (Fig 2) . 20 4-1BBL was found to be expressed following stimulation on professional APCs including DCs and macrophages as well as activated B cells in both human and mice. 13, 16, 21, 23, 34 Human 4-1BBL message was detected as early as 30 minutes following stimulation through immobilized CD3 monoclonal antibody (mAb) and peaks at 1 hour. 13 4-1BBL was also present at high levels in the sera of some patients with hematological diseases 35 as well as on some carcinoma cell lines. 36 The inducible expression pattern of 4-1BBL was similar to that of B7-1 and B7-2 in the CD28:B7 pathway. The costimulatory molecules B7-1 and B7-2 were expressed at very low levels in resting APCs and upregulated upon activation by surface Ig. 37 For B7-1, the expression was predominantly found on B cells and upon stimulation the expression increased between 24 and 72 hours, however after 72 hours, the expression declined rapidly. 37 B7-2 was upregulated more rapidly on both professional APCs and lymphocytes but had a similar peak expression time between 24 and 96 hours. 37 Although the B7 and 4-1BBL costimulatory molecules were inducible, 4-1BBL reached its peak expression within a shorter time following stimulation.
Role of 4-1BB:4-1BBL in primary immune responses
The existence of 4-1BB À/À and 4-1BBL À/À knockout mice 38, 39 has allowed a number of investigations into the necessity of 4-1BB:4-1BBL in immune responses. Kwon et al 39 showed that T cells from 4-1BB À/À mice had enhanced proliferation in response to mitogens, or a-CD3. However, the T-cell immune responses of 4-1BB À/À mice, as measured by cytokine production and CD8
þ Tcell cytotoxic T lymphocyte (CTL) activity, were diminished. In 4-1BBL À/À mice, Bertram et al 38 showed that in the initial expansion of D b /NP366-374-specific CD8 þ T cells in response to influenza virus infection, 4-1BBL À/À mice showed a decrease in virus-specific T cells late in the primary response. 
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In mice, it has been shown that in conjunction with ''signal one'', the interaction of 4-1BBL with 4-1BB provides costimulatory signals to both CD4 þ and CD8 þ T cells through the activation of NF-kB, c-Jun and p38 downstream pathways (Fig 3) . 40 Although stimulation of the 4-1BB:4-1BBL signaling pathway leads to both CD4 þ and CD8
þ T-cell activation, 19, 41, 42 evidence has shown that it caused the preferential expansion of CD8 þ T cells. Shuford et al 43 used mAbs to show that 4-1BB signaling markedly enhanced interferon-g production from CD8
þ T cells and that the a-4-1BB mediated proliferation of CD8 þ T cells appeared to be IL-2 independent. Use of a-4-1BB Ab, in vitro, to stimulate CD8 þ T cells with downregulated CD28 showed that CD28 expression was restored, while expression of the memory marker CD45RO and CC chemokine receptor 6 (CCR6) and the content of granzyme B were also enhanced. Lee et al 44 showed that 4-1BB promotes the survival of CD8
þ T lymphocytes by increasing expression of antiapoptotic genes bcl-X L and bfl-l via 4-1BB-mediated NF-kB activation preventing AICD. As 4-1BB triggering could be protracted from the TCR signal, 4-1BB agonists may function through these mechanisms to enhance or rescue suboptimal immune responses. 45 The evidence suggests that regulatory signals delivered by the 4-1BB receptor play an important role in the regulation of CD8 þ T cells in cellular immune responses to Ag. 4-1BB also plays a marked role in the differentiation of effector memory CD8 þ T cells. 46 Although the 4-1BB signaling pathway was shown to lead to a preferential stimulation of CD8 þ compared with CD4 þ T cells, selective depletion of CD4 þ T-cell subpopulation in vivo with mAb resulted in the loss of the antitumor effect.
47 CD4 þ T cells may not be required during the generation of the initial immune response but may be important in the generation or maintenance of long-term memory responses. 48 It was found that the expansion and cytolytic function of tumor reactive CD8
þ T cells was enhanced by CD4 þ T cells. 49 Apart from T cells, other cells in the immune system have been shown to be influenced by 4-1BB:4-1BBL during immune responses. Crosslinking of 4-1BBL on macrophages by 4-1BBFc plus a-Fc stimulates the production of IL-6, IL-8 and TNF-a but not IL-12. 50 The engagement of 4-1BBL, in the context of a-IgM providing signal 1, relays costimulatory signals to stimulate B-cell proliferation. 21 Recent studies using transgenic mice expressing 4-1BBL under control of MHC II I-Ea promoter showed that they developed progressive splenomegaly and selective depletion of B220 þ B cells accompanied with low levels of circulating IgG. In addition, these mice exhibited defective humoral responses to Ag challenge suggesting that 4-1BBL may regulate humoral immune responses through the control of the survival of B cell. 51 Selective depletion of NK cells in mice using mAb completely abrogated the antitumor effect in various animal tumor models, 22, 52 indicating that NK cells may modulate either immunoregulatory or effector function in response to 4-1BB:4-1BBL signaling. Activation of 4-1BB in the neutrophil abrogates GM-CSF-mediated anti-apoptosis, which may be associated with massive neutrophil accumulation and consequent tissue damage. 24 Triggering of the 4-1BB receptor in human monocytes was able to activate IL-8 and TNF-a production whereas it inhibited IL-10 production. More recently a new function for 4-1BB as a DC activator was observed. 4-1BB was shown to induce IL-6 and IL-12 production as well as upregulate the costimulatory molecules B7-1 and B7-2 23 upon receiving stimulus from adjacent APC or tumor cells. 23, 53, 54 Role of 4-1BB:4-1BBL in secondary immune responses Most of the evidence of the involvement of 4-1BB:4-1BBL in secondary immune responses has been reported following studies of viral infections in mice. BALB/c mice immunized with influenza strain X-31 were sacrificed 3 weeks after treatment and the splenocytes were isolated. The cells were then restimulated in vitro with the H-2 d B lymphoma, K46J, expressing 4-1BBL and the influenza virus peptide. Blockade of the 4-1BB:4-1BBL signaling through the inclusion of a soluble form of the 4-1BB receptor during this in vitro restimulation partially abrogated the secondary CTL responses. 55 Using LCMV, either 4-1BBL-deficient or wild-type mice were immunized with a (LCMV) peptide NP396-404. When agonistic a-4-1BB Ab was given, the CD8 þ T-cell responses in 4-1BBL-deficient mice were augmented to levels similar to those in wild-type mice immunized with the same agent. Upon challenge, wild-type mice still had epitope-specific Figure 3 Diagrammatic representation of 4-1BB:4-1BBL-mediated signaling events at the cell surface. Two signals are necessary to activate the naïve T cell, the first is through TCR:MHC:Ag, while signal two involves the costimulatory signals (e.g. CD28:B-7, 4-1BB:4-1BBL). Adhesion molecules (eg. CD40:CD40L, ICAM-1:LFA-1, LFA-3:CD2) are important during the interaction as they are thought to extend the period of time during which the two cells are held close together. Upon trigging of 4-1BB receptor and TCR, NFkB, c-Jun, p38 downstream pathway are activated which activate cytokine production and secretion. Activation of NF-kB also promotes the survival of CD8 þ T lymphocytes by increasing expression of antiapoptotic genes bcl-X L and bfl-l.
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ATC Cheuk et al T cells and were protected against viral infection, demonstrating that peptide vaccination can induce longterm protection. However, 4-1BBL À/À mice were not protected from the infection 56 suggesting that the 4-1BB:4-1BBL pathway was crucial for the development of the secondary immune responses.
The latter timing of 4-1BB expression following T-cell activation suggests that 4-1BB:4-1BBL may be important in the late immune response when the CD28:B7 signaling is dampening. However, signals through 4-1BB:4-1BBL have been shown to be involved in the regulation of proliferation and survival of lymphocytes and appears to be able to work in both a CD28 independent and dependent manner. 57, 58 In the absence of CD28, 4-1BB molecules have been able to prevent AICD and rescue and sustain ongoing immune responses.
58,59
Can the 4-1BB:4-1BBL pathway work in a CD28 dependent manner?
The B7:CD28 costimulatory pathway seems to be essential for the induction of 4-1BB, whereas 4-1BB expression provides its own positive feedback loop. The CTLA4 receptor limits T-cell-mediated immune responses while together the CD28 and 4-1BB pathways facilitate both T-cell survival and effector cell development. 58, 59 We found that 4-1BBL can enhance antitumor responses in the absence of CD28, however for protective immunity, CD28:B7 signaling was necessary. 60, 61 We demonstrated that using the A20 B-cell lymphoma model in CD28
À/À mice, 4-1BBL enhanced antitumor responses even in the absence of CD28; however, the CD28:B7 pathway was required for long-term protective immunity against the parental A20 tumor. These results support the idea that different immune responses vary in their dependence on costimulation and suggest a role for 4-1BBL in augmenting suboptimal CTL responses in vivo.
4-1BB:4-1BBL in tumor immunogene therapy
The aim of tumor immunotherapy has been to generate long-lasting functionally active CD8 þ T cells specific for the tumor cells. Tumors that develop are thought to have escaped immune surveillance. One reason for this belief is that patients with immunosuppressive diseases such as AIDS tend to develop tumors at an increased frequency. Tumors may evade the immune system in one or more of the following ways: through (1) low-level expression of the major histocompatability complex (MHC) I molecules; (2) poor costimulatory molecules expression; (3) absence of recognizable tumor Ags; (4) the secretion of immunosuppressive substances such as FasL. A more thorough review of these can be found elsewhere. 62 In order to activate T cells against the tumor, strategies must be developed that overcome the ways in which tumors escape the immune system or the ways in which the immune system limits it's response such as through CTLA-4 signaling. 63 A number of studies have demonstrated effective antitumor targeting in clinical trials using the costimulatory molecules but to date these have solely utilized the B7:CD28 pathway (Table 1) . [64] [65] [66] [67] [68] Autoimmune disease may be initiated when T cells are inadvertently activated to respond to normal tissues perhaps due to concurrent viral infection. Evidence of the ways in which viruses can mis-direct the immune system and lead to autoimmune disease in humans are discussed in detail elsewhere. 69 In immunotherapy, a balance has to be reached in which CD8 þ T cells are stimulated to kill infected or malignant cells but are not inadvertently stimulated to recognize normal tissues and cause the autoimmune destruction of healthy organs. Myers et al 70 showed that 4-1BB and Toll-like receptor led to the survival of specific effector CD8 þ T cells with suppressive recall potential, which may explain the dual role that 4-1BB activation plays in mediating tumor clearance and preventing autoimmune disease. Although, immunotherapy protocols seek to avoid the induction of normal tissue destruction there are occasions when relatively mild side effects such as vitiligo, opportunistic infections and EBV-related lymphoproliferative disease do occur. However these autoimmune-related side effects are treatable and are generally considered to be a reasonable trade-off 71 for the removal of a life-threatening tumor.
In the remainder of this paper, we will focus solely on some of results of preclinical studies using 4-1BB:4-1BBL as a vehicle to enhance antitumor responses (Table 2) .
Adoptive transfer of ex vivo costimulated T cells
One strategy has involved the isolation of T cells from tumor-bearing mice which were expanded, stimulated ex vivo and transferred back into tumor-bearing mice. Recently, this approach was used by Strome et al, 72 who isolated T cells from the tumor-draining lymph node of mice bearing disseminated micrometastasis of a poorly immunogenic, MHC class I-negative A9P melanoma. The T cells were stimulated through both the CD28 and 4-1BB pathways and then adoptively transferred into another mouse with A9P melanoma. Results showed that a 60% cure rate was achieved.
In a murine fibrosarcoma model tumor-draining lymph nodes (TDLN) were isolated from mice bearing MCA205 tumors. The cells were then stimulated in vitro using a-CD3, a-CD28 and/or a-4-1BB Ab and returned to syngeneic mice bearing MCA205 tumors. The number of pulmonary metastases in the recipient mice were significantly reduced and survival was prolonged in mice which received a-41BB mAb compared with those that did not. 73 These studies demonstrated that the adoptive transfer of ex vivo-stimulated T cells may increase their potential for cancer immunotherapy in some pre-clinical animal studies.
However when applied in humans, adoptive therapy using T cells has some limitations. It has been difficult to generate sufficient T cells ex vivo to transfer back into patients. The functional capacity of CD8 þ T cells has 4-1BB:4-1BB ligand in cancer immunotherapy ATC Cheuk et al been shown to be altered following the in vitro T-cell culturing phase. Even when a large number of functional T cells were generated and transferred into the patient, the adoptive therapy was still unsuccessful by virtue of the range of mechanisms by which tumors evade the immune system. Details of the problems of adoptive transfer of T cells are reviewed in more detail elsewhere. 74 Therapy using a-4-1BB Ab
Another strategy has been to stimulate T cells to target tumors through the injection of Ab into the host. The hypothesis behind this was that if the tumor did not have sufficient costimulatory molecule expression then injecting mAb against 4-1BBL, which binds to 4-1BB on the T cell, would activate the tumor-specific T cell, and lead to tumor cell lyses. Melero et al 47 showed that the intraperitoneal (i.p.) injection of a-4-1BB mAb could eradicate large established tumors in mice, including the poorly immunogenic Ag104A sarcoma and the highly tumorigenic P815 mastocytoma. The immune response induced by a-4-1BB mAb was mediated by both CD8 þ and CD4 þ T cells and was accompanied by a marked augmentation of tumor-specific CTL activity.
Treatment of 3-day intracranial MCA 205 sarcoma or GL261 glioma with mAb against 4-1BB (3E1 and 1D8) given i.p. resulted in the cure of four and two of five of the MCA205 sarcoma-bearing mice. Treatment of mice with either mAb led to prolongation of survival and cure of disease in two of each of the five mice harboring a GL261 glioma. 75 It was also noted that the successful treatment of intracranial tumors induced concomitant regression of subcutaneous tumors. However, no antitumor effects against the poorly immunogenic B16/D5 melanoma were observed.
In an orthotopic model of metastatic colon carcinoma established in the liver of mice, the authors generated an effective tumor-specific CD8 þ T-cell response through a combination of IL-12 gene therapy and systemic i.p. delivery of an agonistic mAb against 4-1BB. In the IL-12 plus a-4-1BB combination treatment, the innate and adaptive antitumor immune responses were synergistic, as animals bearing simultaneous hepatic and multiple pulmonary metastases were quantitatively cured of their diseases. Both NK and CD8 þ T cells were necessary in maintaining the long-term antitumor immunity, as depletion of either cell type in the cured animals abolished their abilities to reject tumor cells implanted at distal sites. 76 In a systemically delivered murine JC breast cancer treated with a-4-1BB mAb i.p. there was regression of pre-established tumors and a survival rate of 87%. The group also compared the systemic agonistic Ab with local 4-1BBL gene delivery in combination with IL-12. They found that the latter method was also able to eradicate established tumor with a similar survival rate of 78%. However, only survivors who had received treatment with the IL-12 and 4-1BBL genes showed significantly potent, systemic and tumor-specific T-cellmediated immunity. 77 It would appear that the transfection of 4-1BBL cDNA into tumor cells to make a whole cell tumor vaccine may not be as effective at inducing antitumor responses when compared to the use of a-4-1BB mAb. In the murine sarcoma cell line Ag104, the tumor cells which express 4-1BBL had no therapeutic activity unless they were also transfected with B7-1. 78 However, the injection of a-4-1BB Ab into mice with the same tumor (Ag104) caused tumor destruction. 47 In addition mAb against the T-cell activation molecule 4-1BB was effective in the treatment of established mouse tumors. In the Ag104 tumor model, 4-1BBL cDNA did not engage antitumor immune responses without the help of CD28:B7 signaling, thus, using mAb can provide a more effective antitumor immune response even in the absence of CD28:B7 signaling. However mAbs may still not provide the better treatment as 4-1BB mAbs have been shown to abrogate T-cell-dependent humoral immune responses in vivo through the induction of helper T-cell anergy. 79 Moreover in a personal communication by Dr R Mittler (Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30329, USA) quoted by Hellstrom and Hellstrom, 80 mAb may induce or worsen autoimmune diseases that were mediated by CD8 þ and/or CD4 þ T cells.
Whole cell vaccines created using 4-1BBL
The most common immunotherapeutic use of 4-1BBL to date has been the modification of tumor cells with 4-1BBL cDNA for whole cell vaccinations. The theory behind this treatment is that if a tumor cell already expresses a medley of mostly undefined tumor Ags then the modification of the tumor cell to improve its ability to act as an APC, would avoid the need to define these Ags, while costimulatory molecules transfection would provide an abundance of signal two.
Mice inoculated with murine P815 mastocytoma or A104A sarcoma cell lines expressing 4-1BBL develop a strong CTL response and long-term immunity against wild-type tumor. The optimal effect of 4-1BBL in CTL stimulation required B7-CD28 signaling since Ab blockade of this downregulated the expression of 4-1BB on T cells and decreased CTL activity. 78 In studies using the A20, B-cell lymphoma cell line, 81 mice injected with tumors expressing the vector backbone alone (A20/CMV) or B7-1 (A20/B7-1) developed tumors within 25 days of subcutaneous injection. In contrast, mice injected with A20/4-1BBL were tumor free for the 150-day follow-up period, and few (25%) of the mice injected with A20/B7-2 developed tumors. Almost all mice which resisted the initial tumor challenge rejected a later systemic challenge with the parental tumor cell line. Tumorigenicity experiments using nude mice indicated the requirement for T cells for variant rejection while Ab blocking studies indicated that both CD28 and 4-1BB signaling were involved in CTL-mediated tumor lyses ex vivo.
Introduction of 4-1BBL cDNA into NRS1, a murine squamous cell carcinoma, efficiently elicited antitumor immune responses in syngeneic mice which acquired specific immunity against wild-type tumor. 82 T-cell depletion studies showed that CD8
þ , but not CD4 þ T cells were essential for tumor eradication. In addition to B7-1 and B7-2, the host-derived 4-1BBL was also found to be involved in the secondary antitumor responses. 82 Xiang, 83 transfected 4-1BBL into the moderately immunogenic murine T-cell lymphoma EL4 cell line and the poorly immunogenic, highly metastatic to the lung, variant of BL6 melanoma cell line called BL6-10. Expression of the costimulatory molecule 4-1BBL was able to induce tumor regression of the modified EL4/4-1BBL but not BL6-10/4-1BBL tumor cell lines in syngeneic BALB/c mice. The tumor regression was mainly mediated by CD8 þ T cells that led to protective immunity against the parental EL4 tumor. The result reaffirmed the antitumor potential of engineered tumor cells expressing the costimulatory molecule 4-1BBL, especially in combination with other costimulatory molecules such as B7-1 83 and/or B7-2 81 in cancer vaccines. In a colon cancer model, syngeneic BALB/c mice received an intrahepatic injection of the poorly immunogenic MCA26 colon cancer cells. 52 Various combinations of replication-defective adenoviruses expressing IL-12 and 4-1BBL cDNA were injected into the established liver tumor. Changes in tumor size and animal survival were then monitored. The long-term survival rate of mice treated with the combination of IL-12 and 4-1BBL were significantly improved over that of animals in the control groups. In vivo depletion of NK cells or CD8 þ T cells completely abolished the long-term survival advantage of the IL-12 plus 4-1BBL-treated animals. The systemic immunity induced by this combination treatment protected animals against a subcutaneous challenge with parental MCA26 cells. Adenovirus-mediated transfer of IL-12 and 4-1BBL cDNAs directly into liver tumors resulted in tumor regression that required both NK and CD8 þ T cells and generated a potent, long-lasting antitumor immunity.
In a murine liver metastases of breast cancer model, intratumor adenoviral-mediated gene transfer of the 4-1BB led to regression of a pre-established tumor and the survival rate was 78%. 52 An alternative method for the creation of a whole cell vaccine was the transfer of cDNAs encoding fragments of mAb against 4-1BB. This vaccine appeared to stimulate the immune system in a similarly efficacious manner to a-4-1BB mAbs. Ye et al, 84 constructed a vector encoding cell-bound single-chain Fv fragments from 1D8 a-4-1BB. They transfected the vector into K1735 melanoma cells which expressed low levels of MHC class I molecules and were poorly immunogenicity. The transfected cells induced a strong type 1 T-helper cell response, for which CD4 þ but not CD8 þ T lymphocytes were necessary and this response also involved NK cells. Vaccinated mice rejected established wild-type K1735 tumors growing as subcutaneous nodules or in the lung.
There are technical difficulties associated with whole cell vaccine protocols, primary tumor cells are very difficult to culture and transfect ex vivo and it has been difficult to obtain a large enough gene-modified population for transplantation back into patients. 85 Most whole cell vaccine models in mice have involved injecting the modified live tumor cells into mice in the first instance and then challenging with primary tumor cells. From the lack of publications to the contrary, and our own unpublished experiences, it would appear that eliminating established tumors using whole cell vaccines is also very difficult.
Capacity of the costimulatory molecules to enhance antitumor responses
It has not been easy to compare the efficacy of different costimulatory molecules in the various tumor immunotherapy protocols, as different tumors have an individual molecular signature of gene expression. This signature varies within the cells of the tumor and with tumor progression. To date only a small number of studies have directly compared the costimulatory molecules within a single tumor model system. 78, 81 These studies have shown that transfection of 4-1BBL cDNA into a tumor cell which had innate B7-1 and B7-2 expression could create a whole cell tumor vaccine which was more efficacious than transfection of the same cells with either B7-1 or B7-2 alone.
In general, 4-1BB receptors were only inducible on activated T cells and the costimulatory pathway, B7/ CD28 appeared to be necessary to activate T cells through the primary T-cell activation or secondary responses in 4-1BB knockout mice.
38,39 4-1BB:4-1BBL acts as an amplifier of the existing costimulatory signals but B7:CD28 was still the primary and generally the most effective mode of initiating the immune response (at least in antitumor responses). 81 Coexpression of 4-1BBL and B7-1 in the poorly immunogenic AG104A sarcoma enhanced the induction of effector CD8 þ T cells which could reject even the poorly immunogenic wild-type AG104A tumor while neither 4-1BBL nor B7-1 single transfectants were as effective. 78 NRS1 was a murine squamous cell carcinoma that constitutively expresses B7-1 at high levels, yet it was the introduction of the 4-1BBL cDNA that efficiently elicited antitumor immune responses in syngeneic mice which then acquired specific immunity against the wild-type tumor. 82 Guinn et al 61 showed that in a A20 model in mouse, protective immunity against parental tumors involved both the 4-1BBL and CD28 pathways. All these data suggested a synergistic effect between the B7:CD28 and 4-1BB:4-1BBL costimulatory pathways. B7/CD28 pathway does not always protect the host against wild-type tumor but the B7/CD28 pathway was required for the optimal effect of 4-1BB:4-1BBL. 78 The level of 4-1BBL expression on modified tumor cells also appears to be important. Higher levels of the costimulatory molecules appeared to be more effective in inducing antitumor responses. Guinn et al 61 showed that 25% of mice injected with A20 lymphoma cells expressing low levels of 4-1BBL developed tumors in the 150 days post-injection follow-up period but no tumors developed in mice injected with A20 expressing moderate or high levels of 4-1BBL. Hence, for the development of a more effective antitumor vaccine, a more discerning strategy might involve the modification of the tumor cell to express several different costimulatory molecules each with a high level of expression.
Conclusion
In animal studies, 4-1BB:4-1BBL seems to give very promising results in anti-tumor therapy and has provided us with a lot of information regarding the basic biology of costimulation. However, there appears to be a long way to go for this to apply to human clinical trials. Many technical problems still need to be solved and continuing efforts in animal models and human clinical trials will help provide the information necessary to improve therapies in the future.
